NCT03435666: A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition

NCT03435666
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Ph+ase 1
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 60 Years åÊ (Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Known symptomatic or untreated central nervous system (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03435666

Comments are closed.

Up ↑